Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study

Thrombosis Research

Volumn 166, Issue , 2018, Pages 54-59

  van Es, Nick ^a   Hisada, Yohei ^b   Di Nisio, Marcello ^c   Cesarman, Gabriela ^d   Kleinjan, Ankie ^a   Mahé, Isabelle ^e   Otten, Hans Martin ^f   Kamphuisen, Pieter W ^g,h   Berckmans, René J ^a   Büller, Harry R ^a   Mackman, Nigel ^b   Nieuwland, Rienk ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e HÔPITAL LOUIS MOURIER   (France)

^f SLOTERVAART HOSPITAL   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h TERGOOI HOSPITAL   (Netherlands)

Author keywords

Biomarkers; Blood coagulation; Neoplasms; Predictive value of tests; Pulmonary embolism; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; PROCOAGULANT; THROMBOPLASTIN;

ADULT; ADVANCED CANCER; ARTICLE; BIOASSAY; CANCER PATIENT; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; EXOSOME; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; COMPLICATION; METABOLISM; NEOPLASM; PATHOLOGY;

COHORT STUDIES; EXTRACELLULAR VESICLES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 85045249092     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2018.04.009     Document Type: Article

References (30)

1. Timp, J.F., Braekkan, S.K., Versteeg, H.H., Cannegieter, S.C., Epidemiology of cancer-associated venous thrombosis. Blood 122 (2013), 1712–1723.
2. Lyman, G.H., Bohlke, K., Khorana, A.A., Kuderer, N.M., Lee, A.Y., Arcelus, J.I., Balaban, E.P., Clarke, J.M., Flowers, C.R., Francis, C.W., Gates, L.E., Kakkar, A.K., Key, N.S., Levine, M.N., Liebman, H.A., Tempero, M.A., Wong, S.L., Somerfield, M.R., Falanga, A., Prestrud, A.A., Falanga, A., Bohlke, K., Khorana, A.A., Kuderer, N.M., Lee, A.Y., Arcelus, J.I., Balaban, E.P., Clarke, J.M., Flowers, C.R., Francis, C.W., Gates, L.E., Kakkar, A.K., Key, N.S., Levine, M.N., Liebman, H.A., Tempero, M.A., Wong, S.L., Somerfield, M.R., Falanga, A., Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J. Clin. Oncol. 31 (2013), 654–656.
3. Mandalà M., Falanga, A., Roila, F., ESMO Guidelines Working Group, venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann. Oncol. 21:Suppl. 5 (2010), v274–6.
4. Farge, D., Debourdeau, P., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., Brilhante, D., Falanga, A., Gerotzafias, G.T., Haim, N., Kakkar, A.K., Khorana, A.A., Lecumberri, R., Mandala, M., Marty, M., Monreal, M., Mousa, S.A., Noble, S., Pabinger, I., Prandoni, P., Prins, M.H., Qari, M.H., Streiff, M.B., Syrigos, K., Bounameaux, H., Büller, H.R., International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 11 (2013), 56–70.
5. György, B., Szabó T.G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László V., Pállinger, É., Pap, E., Kittel, Á., Nagy, G., Falus, A., Buzás, E.I., Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68 (2011), 2667–2688.
6. Gardiner, C., Harrison, P., Belting, M., Böing, A., Campello, E., Carter, B.S., Collier, M.E., Coumans, F., Ettelaie, C., van Es, N., Hochberg, F.H., Mackman, N., Rennert, R.C., Thaler, J., Rak, J., Nieuwland, R., Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. J. Extracell. Vesicles. 4 (2015), 1–14.
7. van den Berg, Y.W., Osanto, S., Reitsma, P.H., Versteeg, H.H., The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119 (2012), 924–932.
8. Cesarman-Maus, G., Braggio, E., Lome-Maldonado, C., Morales-Leyte, A.L., Fonseca, R., Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb. Res. 133 (2014), 606–609.
9. Kakkar, A.K., DeRuvo, N., Chinswangwatanakul, V., Tebbutt, S., Williamson, R.C., Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346 (1995), 1004–1005.
10. a Khorana, A., a Ahrendt, S., Ryan, C.K., Francis, C.W., Hruban, R.H., Hu, Y.C., Hostetter, G., Harvey, J., Taubman, M.B., Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 13 (2007), 2870–2875.
11. Khorana, A.A., Francis, C.W., Menzies, K.E., Wang, J.-G., Hyrien, O., Hathcock, J., Mackman, N., Taubman, M.B., Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haemost. 6 (2008), 1983–1985.
12. van Doormaal, F.F., Kleinjan, A., Berckmans, R.J., Mackman, N., Manly, D., Kamphuisen, P.W., Richel, D.J., Büller, H.R., Sturk, A., Nieuwland, R., Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb. Haemost. 108 (2012), 160–165.
13. Bharthuar, A., Khorana, A.A., Hutson, A., Wang, J.-G., Key, N.S., Mackman, N., Iyer, R.V., Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb. Res. 132:2 (2013), 180–184.
14. Hernández, C., Orbe, J., Roncal, C., Alvarez-Hernandez, M., Martinez de Lizarrondo, S., Alves, M.T., García Mata, J., a Páramo, J., Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb. Haemost. 110 (2013), 598–608.
15. Thaler, J., Ay, C., Mackman, N., Bertina, R.M., Kaider, A., Marosi, C., Key, N.S., Barcel, D.A., Scheithauer, W., Kornek, G., Zielinski, C., Pabinger, I., Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J. Thromb. Haemost. 10 (2012), 1363–1370.
16. Berckmans, R.J., Sturk, A., Van Tienen, L.M., Schaap, M.C.L., Nieuwland, R., Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 117 (2011), 3172–3180.
17. Lee, R.D., Barcel, D.A., Williams, J.C., Wang, J.G., Boles, J.C., Manly, D.A., Key, N.S., Mackman, N., Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb. Res. 129 (2012), 80–85.
18. Choudhury, J.B., Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat. Med. 21 (2002), 1129–1144.
19. Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc., 94, 1999, 496.
20. Hisada, Y., Alexander, W., Kasthuri, R., Voorhees, P., Mobarrez, F., Taylor, A., McNamara, C., Wallen, H., Witkowski, M., Key, N.S., Rauch, U., MacKman, N., Measurement of microparticle tissue factor activity in clinical samples: a summary of two tissue factor-dependent FXa generation assays. Thromb. Res. 139 (2016), 90–97.
21. Claussen, C., Rausch, A.-V., Lezius, S., Amirkhosravi, A., Davila, M., Francis, J.L., Hisada, Y.M., Mackman, N., Bokemeyer, C., Schmalfeldt, B., Mahner, S., Langer, F., Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. Thromb. Res. 141 (2016), 39–48.
22. Parhami-Seren, B., Butenas, S., Krudysz-Amblo, J., Mann, K.G., Immunologic quantitation of tissue factors. J. Thromb. Haemost. 4 (2006), 1747–1755.
23. Lacroix, R., Judicone, C., Mooberry, M., Boucekine, M., Key, N.S., Dignat-George, F., The ISTH SSC workshop, standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and Haemostasis SSC collaborative workshop. J. Thromb. Haemost., 2013, 10.1111/jth.12207 PMID 23551930 (J Thromb Haemost. 2013 Apr 2).
24. Reitter, E.M., Kaider, A., Ay, C., Quehenberger, P., Marosi, C., Zielinski, C., Pabinger, I., Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. J. Thromb. Haemost. 14 (2016), 294–305.
25. Tesselaar, M.E.T., Romijn, F.P.H.T.M., Van Der Linden, I.K., Prins, F.A., Bertina, R.M., Osanto, S., Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J. Thromb. Haemost. 5 (2007), 520–527.
26. Zwicker, J.I., Liebman, H.A., Bauer, K.A., Caughey, T., Campigotto, F., Rosovsky, R., Mantha, S., Kessler, C.M., Eneman, J., Raghavan, V., Lenz, H.-J., Bullock, A., Buchbinder, E., Neuberg, D., Furie, B., Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br. J. Haematol. 160 (2013), 530–537.
27. Ay, C., Vormittag, R., Dunkler, D., Simanek, R., Chiriac, A.-L., Drach, J., Quehenberger, P., Wagner, O., Zielinski, C., Pabinger, I., D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis study. J. Clin. Oncol. 27 (2009), 4124–4129.
28. Vormittag, R., Simanek, R., Ay, C., Dunkler, D., Quehenberger, P., Marosi, C., Zielinski, C., Pabinger, I., High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 2176–2181.
29. Ay, C., Dunkler, D., Simanek, R., Thaler, J., Koder, S., Marosi, C., Zielinski, C., Pabinger, I., Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol. 29 (2011), 2099–2103.
30. Pabinger, I., Thaler, J., Ay, C., Biomarkers for prediction of venous thromboembolism in cancer. Blood 122 (2013), 2011–2018.